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nective tissue growth factor (CTGF) plays a key role in renal fibrosis.
Urinary CTGF is elevated in various renal diseases and may have
biomarker potential. However, it is unknown which processes con-
tribute to elevated urinary CTGF levels. Thus far, urinary CTGF was
considered to reflect renal expression. We investigated how tubular
dysfunction affects urinary CTGF levels. To study this, we adminis-
tered recombinant CTGF intravenously to rodents. We used both
full-length CTGF and the NH2-terminal fragment, since the NH2-
fragment is the predominant form detected in urine. Renal CTGF
extraction, determined by simultaneous arterial and renal vein sam-
pling, was 18  3% for full-length CTGF and 21  1% for the
NH2-fragment. Fractional excretion was very low for both CTGFs
(0.02  0.006% and 0.10  0.02%, respectively), indicating that
99% of the extracted CTGF was metabolized by the kidney. Immu-
nohistochemistry revealed extensive proximal tubular uptake of
CTGF in apical endocytic vesicles and colocalization with megalin.
Urinary CTGF was elevated in megalin- and cubilin-deficient mice
but not in cubilin-deficient mice. Inhibition of tubular reabsorption by
Gelofusine reduced renal uptake of CTGF and increased urinary
CTGF. In healthy volunteers, Gelofusine also induced an increase of
urinary CTGF excretion, comparable to the increase of 2-micro-
globulin excretion (r  0.99). Furthermore, urinary CTGF correlated
with 2-microglobulin (r  0.85) in renal disease patients (n 108),
and only 2-microglobulin emerged as an independent determinant of
urinary CTGF. Thus filtered CTGF is normally reabsorbed almost
completely in proximal tubules via megalin, and elevated urinary
CTGF may largely reflect proximal tubular dysfunction.
proximal tubular reabsorption; biomarker; megalin
CONNECTIVE TISSUE GROWTH FACTOR (CTGF) is an important
profibrotic growth factor in chronic kidney disease (CKD).
Elevated urinary connective tissue growth factor levels
(uCTGF) are reported in diabetic nephropathy (DN), chronic
allograft nephropathy (CAN), IgA nephropathy, focal segmen-
tal glomerular sclerosis, and idiopathic membranous nephro-
pathy (iMN) (1, 6, 17, 24). uCTGF relates to markers of
disease severity in CKD. In type I DN, uCTGF excretion
correlated with urinary albumin excretion and glomerular fil-
tration rate (GFR) and in CAN with biopsy histology and
proteinuria (6, 24). In iMN, uCTGF was associated with
proteinuria and GFR, and uCTGF was an independent predic-
tor of deterioration of renal function (1). However, despite
increasing evidence regarding the biomarker potential of
uCTGF, interpretation of urinary levels is hampered by lack of
understanding of the processes contributing to elevated levels.
Previously, elevated uCTGF was considered to reflect in-
creased intrarenal production (26). In many renal diseases,
overexpression of CTGF was observed in inflammatory glo-
merular lesions and tubulointerstitial fibrotic areas (16, 31).
However, we hypothesized that reduced tubular reabsorption
might contribute importantly to increased uCTGF excretion.
To investigate this, we studied whether CTGF is filtered and
tubularly reabsorbed and whether impairment of tubular reab-
sorption results in increased uCTGF excretion. We quantified
renal tubular uptake of recombinant CTGF after intravenous
administration in rodents and evaluated the effect of inhibition
of proximal tubular reabsorption on uCTGF in healthy rodents
and humans. In addition, we examined the correlation between
urinary levels of CTGF and 2-microglobulin (2M), a sensi-
tive marker of tubular dysfunction, in renal disease. The
secondary objective was to identify the endocytic receptor
involved in proximal tubular reabsorption of CTGF.
MATERIALS AND METHODS
Recombinant CTGF proteins and anti-CTGF antibodies. Recom-
binant CTGFs and anti-CTGF antibodies were supplied by Fibrogen
(San Francisco, CA). The recombinant human CTGFs were produced
in a baculovirus expression system in Chinese Hamster Ovary cell
lines cultured in hollow-fiber fermentors. The proteins were purified
by CTGF-affinity and cation exchange chromatograpy. Recombinant
full-length CTGF comprised all four domains (Q27-A349), and the
NH2-terminal fragment comprised domains 1 and 2 (Q27-A178).
Gelofusine. We purchased Gelofusine (40 g/l) from Braun (Oss,
The Netherlands). Gelofusine is a modified gelatin consisting of
polypeptides with an average molecular mass of 30 kDa. In previous
studies, we have shown that Gelofusine effectively blocks tubular
reabsorption of low molecular mass proteins (30).
Animal experiments. Pharmacokinetic studies were performed in
mice and rats. All experiments were approved by the Animal Ethical
Commission of the University of Utrecht and performed in accor-
dance with national guidelines for the care and handling of animals.
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C57Bl/6J mice (12 wk old; Harlan, Horst, The Netherlands) re-
ceived recombinant human CTGF by tail vein injection (single dose)
or by intraperitoneal infusion (3 days) using micro-osmotic pumps
(model 1003D; ALZET, Cupertino, CA). To evaluate the plasma
disappearance and uptake in the kidneys, mice were killed at various
time points after bolus injection of full-length CTGF or NH2-CTGF
(12.5–50 pmol/g body wt). Kidneys were harvested, weighed, and
processed for ELISA or immunohistochemistry, as described below.
To evaluate the effects of inhibition of proximal tubular reabsorption,
a separate group of mice received Gelofusine (40 g/l; Braun) either by
tail vein injection (5 l/g body wt) 1–2 min before NH2-CTGF
injection in the other tail vein (n 3) or by tail vein injection (10 l/g
body wt) during NH2-CTGF intraperitoneal infusion (0.6 pmol/min)
by micro-osmotic pump 3 days after intraperitoneal implantation
under isoflurane anesthesia (n  3).
To identify the endocytic receptors involved in tubular reabsorption
of (endogenous) CTGF, urine was collected during a 24-h period from
mice deficient for cubilin or megalin/cubilin, obtained by crossing
mice bearing floxed cubilin alleles or both cubilin and megalin floxed
alleles with Mox2-Cre mice. Surviving offspring exhibited a mosaic
pattern of cubilin deficiency or megalin and cubilin deficiency (11).
Deletion of cubilin and megalin varied from 70% to over 95%.
Age-matched wild-type mice were used as controls. Endogenous
uCTGF levels were determined by ELISA as described below.
Studies in rats were performed to quantify the renal extraction and
fractional excretion (FE). Male Wistar-Kyoto rats (15–17 wk old;
Harlan) were anesthetized with intraperitoneal pentobarbital sodium
(72 mg/kg). The trachea was intubated with a 16-G catheter (Veni-
systems Abbocath-T, Abbott, Ireland). A PE-90 catheter was placed in
the left jugular vein for infusion of solutions, a second PE-10 catheter
was introduced for CTGF infusion, and a third PE-10 catheter for
supplemental anesthetic. The left femoral artery was cannulated with
PE-90 tubing for blood withdrawal and pressure monitoring. A PE-90
catheter was placed in the bladder for urine collection. The left renal
vein was exposed through a ventral midline and left subcostal inci-
sion, to make it accessible for puncture. During surgery, animals
received intravenous infusion of 0.9% NaCl and 6% BSA followed by
1% BSA after 20 min at a rate of 8 ml·kg1·h1. Following surgery,
the infusion rate was reduced to 6 ml·kg1·h1 and maintained
throughout the experiment. The solution also contained 30 mM Inulin
(Inutest; Fresenius Pharma, Linz, Austria) and 25 mM para-aminohip-
puric acid (PAH; Sigma, St. Louis, MO) for clearance measurements.
After a 45-min stabilization period, infusion of full-length CTGF or
NH2-CTGF was started at 54 or 7 pmol·kg1·min1, respectively,
based on pilot clearance studies. Urine was collected at 15-min
intervals. After the start of CTGF infusion (90 min), two arterial blood
samples were taken at an interval of 30 min to determine fractional
CTGF excretion. After a short equilibration period, a third arterial
blood sample was taken simultaneously with puncture of the left renal
vein to determine renal extraction ratios and tubular uptake. Inulin and
PAH were measured as described (32).
Human studies. Effect of impairment of tubular reabsorption on
uCTGF excretion was studied in healthy human volunteers by infu-
sion of Gelofusine and in renal disease patients with varying degrees
of tubular dysfunction. The Gelofusine protocol was approved by the
Ethics Review Committee of the University Medical Center St.
Radboud, and informed consent was obtained from healthy volun-
teers. In accordance with Dutch ethical regulations, all patients con-
sented that blood and urine samples were used for medical research.
The studies were conducted according to the principles of the Decla-
ration of Helsinki.
Three healthy volunteers received infusion of Gelofusine (40 g/l;
Braun), which was started at a rate of 10 ml/min for 5 min followed
by 3 ml/min during 55 min. CTGF levels were measured in urinary
samples taken before the infusion and at 30, 60, and 180 min after the
start of the infusion and in blood samples drawn before and at the end
of Gelofusine infusion.
In a cross-sectional study, 108 patients with renal impairment due
to glomerular diseases were enrolled from March 1995 through March
2004 at the Department of Nephrology, Radboud University Nijme-
gen Medical Center (The Netherlands). Details of the cross-sectional
study have been described (4).
CTGF ELISA. CTGF levels in plasma, urine, and renal homoge-
nates were determined by sandwich ELISA, using specific antibodies
(FibroGen) directed against distinct epitopes in the NH2-terminal
fragment of CTGF, detecting both full-length CTGF and the NH2-
fragment. Frozen renal tissue (stored at 80°C) was homogenized in
lysis buffer [20 mM Tris (Roche, Mannheim, Germany), 150 mM
NaCl (Merck, Darmstadt, Germany), 1% Triton X-100, 10% glycerol,
1 mM EDTA (Riedel-de Haen, Seelze, Germany), 0.1% SDS (Re-
search Organics, Cleveland, OH), 1 mM EGTA, 0.5% sodium deoxy-
cholate, 50 mM NaF, and 2 mM sodium orthovanadate (Sigma), pH
7.4] containing 5% Protease Inhibitor Cocktail (Sigma). The follow-
ing two ELISAs were used: a human CTGF assay for detection of
endogenous CTGF in human samples or recombinant human CTGF in
rodent samples and a rodent CTGF assay for determination of endog-
enous CTGF in the transgenic mice. For the human CTGF assay,
microtiter plates (Maxisorb; Nunc, Roskilde, Denmark) were coated
with capture anti-CTGF monoclonal antibody (5 g/ml; FibroGen).
Subsequently, diluted samples and standards (recombinant human
CTGF; FibroGen) were added and incubated with non-cross-blocking
human anti-CTGF monoclonal antibody conjugated directly to alka-
line phosphatase (0.5 g/ml; FibroGen). Para-nitrophenylphosphate
(Sigma) was used as substrate for the colorimetric reaction. For the
rodent CTGF assay, a similar protocol was applied: goat anti-NH2-
CTGF polyclonal antibody (7.5 g/ml; FibroGen) was used for
coating, and a non-cross-blocking human anti-CTGF monoclonal
antibody was used for detection, followed by incubation with goat
anti-human IgG polyclonal antibody conjugated to alkaline phospha-
tase (1:2,000; Sigma). Recombinant mouse CTGF (FibroGen) was
used for standard curves. Assay sensitivities (lower limits of detec-
tion) were 0.02 pmol/ml for the human CTGF assay and 0.04 pmol/ml
for the rodent CTGF assay. The antibody used for detection in the
human CTGF assay does not cross-react with rodent CTGF. Intra- and
interassay coefficients of variation were within 10%. Plasma levels of
endogenous CTGF in healthy rodents, healthy human subjects, and
renal disease patients are shown in Supplemental Table 1 (Supple-
mental data for this article may be found on the American Journal of
Physiology: Renal Physiology website.).
In addition to the ELISAs detecting both full-length CTGF and the
NH2-fragment, we applied the sandwich ELISA technique to speci-
fically detect full-length CTGF by using two distinct antibodies
directed against the COOH-terminal and NH2-terminal fragment. We
did not measure significant amounts of full-length CTGF in human or
rodent urine, neither in the healthy situation nor in the case of
impaired tubular reabsorption, which is in accordance with previous
reports (6, 12, 19, 27).
Immunofluorescence. Immunostaining for CTGF was performed
on 3 m formalin-fixed paraffin-embedded (FFPE) tissue sections.
After deparaffinization, antigen retrieval was performed by predi-
gestion with Protease XXIV (0.2 M phosphate; Sigma) followed by
blocking of endogenous peroxidase activity (1% H2O2 in phos-
phate/citrate buffer). Sections were incubated with CTGF-specific
human monoclonal antibody (FibroGen) (24 g/ml in PBS/1%
BSA) for 1 h followed by incubation with rabbit anti-human IgG
(1:100, 30 min) (Dako, Glostrup, Denmark). Amplification was
performed with Powervision polyperoxidase goat anti-rabbit IgG
(Klinipath, Duiven, The Netherlands) (30 min) and FITC Tyramide
Amplification Reagent (1:50, 10 min) (PerkinElmer, Boston, MA).
TO-PRO 3 Iodide (Molecular Probes, Eugene, OR) was used for
nuclear counterstaining.
For double immunofluorescence staining for CTGF and megalin, 3
m deparaffinized FFPE sections were pretreated by boiling in
Tris-EDTA buffer, pH 9.0, and incubated with goat anti-rat megalin
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polyclonal antibody (1:50) (Santa Cruz Biotechnology, Santa Cruz,
CA) for 1 h followed by incubation with peroxidase-conjugated rabbit
anti-goat IgG (1:50, 30 min) (Dako) and amplification with FITC
Tyramide Amplification Reagent (1:50, 10 min) (PerkinElmer). Sub-
sequently, sections were incubated with CTGF-specific human mono-
clonal antibody (24 g/ml) (FibroGen) for 1 h followed by incubation
with Alexa Fluor 647-conjugated goat anti-human IgG (1:50, 30 min)
(Molecular Probes).
Slides were mounted in Vectashield (Vector Laboratories, Ontario,
Canada) and visualized by confocal laser scanning microscopy. For all
stainings, incubation with secondary antibody alone served as a
negative control.
Immunohistochemistry. To identify proximal tubules, staining with
Lotus tetragonolobus agglutinin (LTA) was applied (5, 28). Deparaf-
finized FFPE sections (3 m) were pretreated by boiling in citrate
buffer, pH 6.0, and incubated with horseradish peroxidase-conjugated
LTA (Sigma) (1:32) for 1 h followed by incubation with NovaRed for
10 min (Vector Laboratories). Sections were counterstained with
hematoxylin and visualized by a Nikon Eclipse E800 microscope
(Nikon Netherlands, Lijnden, the Netherlands).
Consecutive sections were stained with LTA and anti-CTGF (see
Immunofluorescence). Images of corresponding areas were merged by
digital selection and coloring of LTA-positive areas using Adobe
Photoshop software version 11.0 (Adobe Systems, San Jose, CA).
Measurement of creatinine. Urinary and serum creatinine were
measured with enzymatic assays (J2L Elitech, Labarthe-Inard,
France) for murine samples, DiaSys (Holzheim, Germany) for rat
samples, and Roche (Mannheim, Germany) for human samples (au-
tomated technique).
Measurement of 2M. u2M was measured by ELISA, as described
before (18). To avoid degradation of u2M, subjects ingested 4 g
sodium bicarbonate on the evening before the test. 2M was only
measured in urine with a urinary pH 6.0.
Calculations and statistics. Data, expressed as means  SE, were
compared with Student’s t-test (2-tailed). Paired Student’s t-test was
used for comparison of urinary concentrations in mice and FE in
humans before and after Gelofusine administration. Statistical analy-
sis of subsequent urinary concentrations during Gelofusine infusion in
humans was performed by ANOVA for repeated measures. Correla-
tions were assessed by linear regression. In the patient study, uCTGF,
u2M, plasma CTGF, and serum creatinine were logarithmically
transformed before analysis because of their skewed distribution.
Urinary concentrations were expressed in moles per gram of creati-
nine to correct for differences in urine dilution. GFR was estimated by
the abbreviated Modification of Diet in Renal Disease equation (21).
Renal clearances and FE were calculated by standard formulas. Renal
extraction was calculated as follows:
arterial concentration renal vein concentration
arterial concentration
 100% (1)
Tubular uptake was expressed as a percentage of the amount of CTGF
extracted by the kidney and calculated as follows:
1 urine concentration V˙
arterial concentration ERPF renal vein concentration ERPF V˙  100%
(2)
where V˙ is the urinary flow rate and ERPF the effective renal plasma
flow.
RESULTS
Plasma CTGF is glomerularly filtered, almost completely
reabsorbed by proximal tubules, and only minimally excreted
in urine. First, we investigated the fate of recombinant human
CTGF that was administered intravenously to healthy mice.
Using recombinant human CTGF and human CTGF specific
antibodies, we could distinguish between endogenous and
exogenous CTGF and exclude contribution of locally produced
CTGF to measured tissue levels. We administered both full-
length CTGF and the NH2-terminal fragment but focused our
analyses primarily on NH2-CTGF, since this is the predomi-
nant form detected in urine (6, 12, 19, 27). Intravenous bolus
injection of NH2-CTGF led to rapid accumulation in the renal
cortex (Fig. 1A). Immunofluorescent staining showed abundant
NH2-CTGF in endocytic vesicles in renal proximal tubular
cells (Fig. 1, B-C). Localization in apical vesicles suggested
that circulating NH2-CTGF was glomerularly filtered and sub-
sequently reabsorbed from the luminal fluid. Recombinant
full-length CTGF was also filtered and tubularly reabsorbed
(Fig. 1D). LTA and CTGF staining of consecutive sections
identified the CTGF-containing segments as proximal tubules
(Fig. 2). Thus, in healthy mice, CTGF is glomerularly filtered
and to a large extent endocytosed by proximal tubular cells.
To quantify renal extraction and FE, we performed addi-
tional experiments in anesthetized rats that received CTGF by
continuous infusion. After reaching steady state, kinetic pa-
rameters were calculated from steady-state plasma concentra-
tions and urinary excretion, as summarized in Table 1. For
determination of renal extraction, blood samples were drawn
simultaneously from the renal vein and femoral artery. Renal
NH2-CTGF extraction was 21 1%, which was 74% of that of
inulin. For full-length CTGF, renal extraction was 18  3%.
Tubular uptake was almost complete, resulting in FEs of 1%
(Table 1). Thus, in healthy rats, renally extracted CTGF is
almost completely metabolized by the kidney and minimally
excreted in the urine.
Inhibition of tubular reabsorption reduces renal CTGF
uptake and increases uCTGF excretion. We next studied the
effect of tubular reabsorption impairment on uCTGF. Gelo-
fusine, a modified gelatin clinically applied as a plasma volume
expander, was used to inhibit proximal tubular reabsorption
(13, 30). In mice, intravenous injection of Gelofusine 1–2 min
before intravenous bolus injection of NH2-CTGF reduced cor-
tical NH2-CTGF uptake by 49  11% (P  0.05; Fig. 3A).
Pretreatment with Gelofusine resulted in a comparable de-
crease in cortical uptake of full-length CTGF (Supplemental
Figure). Moreover, a single intravenous bolus dose of Gelo-
fusine during continuous NH2-CTGF infusion by an intraperi-
toneal miniosmotic pump in mice increased urinary NH2-
CTGF 15  1-fold (P  0.05; Fig. 3B).
In addition to experiments with recombinant CTGFs in
mice, we also studied the effect of inhibition of tubular reab-
sorption on urinary excretion of endogenous CTGF in healthy
human volunteers. Although basal levels were low, Gelofusine
infusion induced a 23  1-fold increase in uCTGF (P  0.01),
which was paralleled by an increase in urinary 2-microglobu-
lin (u2M) (r 0.99) (Fig. 4, A and B). FE of CTGF increased
from 0.47  0.1 to 13  3% (P  0.05). These results
demonstrate that, in healthy subjects, diminished tubular re-
uptake of CTGF from the luminal fluid is sufficient to induce
a significant increase of uCTGF.
In renal disease, elevated uCTGF is tightly associated with
tubular dysfunction. To investigate whether uCTGF in renal
disease correlated with urine levels of u2M as a marker of
tubular dysfunction, we analyzed urines of 108 patients with
renal impairment resulting from glomerular diseases. The pa-
tients had varying degrees of tubular dysfunction, as indicated
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by a wide range of u2M levels. General characteristics are
summarized in Supplemental Table 2. We observed a tight
correlation between uCTGF and u2M (r  0.85, P  0.001;
Fig. 5). u2M emerged as the only independent determinant of
uCTGF ( 0.81, P  0.001) in a multiple linear regression
model containing age, estimated GFR (or serum creatinine),
and plasma CTGF, which were all significantly associated with
uCTGF in univariate analysis. This is strong evidence that
Fig. 1. Renal CTGF accumulation after single-dose iv ad-
ministration of recombinant human CTGF in mice. A: esti-
mated renal NH2-CTGF (N-CTGF) levels at different time
points after injection, determined by ELISA. Each dot repre-
sents one animal. Curve fitting, performed with GraphPad
Prism, was by the one-phase exponential decay model. B–
D: immunofluorescence of C57Bl/6J kidney by using human
anti-CTGF (green) and TO-PRO 3 Iodide for nuclear staining
(red), visualized by confocal laser scanning microscopy.
B: N-CTGF-treated animal at 10 min showing abundant
N-CTGF in proximal tubules, intensely staining the brush
border. Magnification 630. C: N-CTGF-treated animal at
30 min showing abundant N-CTGF positive apical endocytic
vesicles in proximal tubular cells. Magnification 1,000.
D: CTGF-treated animal at 6 min showing CTGF in proximal
tubules. Magnification 630. E: saline-treated animal. Mag-
nification 630.
Fig. 2. Colocalization of N-CTGF and Lotus
tetragonobolus agglutinin (LTA), a proximal tu-
bule marker. Consecutive sections of mouse kid-
ney after iv administration of recombinant hu-
man N-CTGF were stained with human anti-
CTGF (green) and LTA (red). CTGF-positive
endocytic vesicles are located exclusively in
LTA-positive proximal tubules. Original magni-
fication 200.
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tubular dysfunction is a major determinant of the uCTGF
increase in renal disease.
Megalin is involved in proximal tubular reabsorption of
CTGF. To identify the endocytic receptor involved in the
proximal tubular reabsorption of CTGF, we studied uCTGF in
transgenic mice with deficiencies of the endocytic receptors
megalin and/or cubilin. These multiligand receptors are known
to be responsible for tubular reabsorption of most of the filtered
proteins (7). In MOX2-Cre transgenic mice with a mosaic
expression pattern of megalin and cubilin in the kidney, ex-
hibiting combined deficiency of both receptors, uCTGF was
very high (14  1.5 nmol/g creatinine), whereas, in cubilin
knockout and wild-type mice, uCTGF levels were below the
level of quantification. There were no differences in plasma
CTGF between these various mouse strains. Immunofluores-
cent staining after intravenous administration of CTGF in
healthy C57Bl/6J mice revealed colocalization of megalin and
CTGF in the cortical (proximal) tubules (Fig. 6). These results
show that proximal tubular endocytosis of CTGF is mediated
by the multiligand receptor megalin.
DISCUSSION
The main finding of our studies is that failure of proximal
tubular reabsorption is a major determinant of increased
uCTGF. In healthy animals, intravenously administered CTGF
was filtered in the glomerulus, but only minimal excretion in
the urine was observed. This was found to be due to almost
Table 1. Renal handling parameters of recombinant human
CTGF in healthy rats
Parameter NH2-Fragment Full-Length CTGF
n 4 4
Body wt, g 323  28 309  11
Mean arterial pressure, mmHg 92  7 101  2
GFR, ml ·kg1 ·min1 (inulin) 7.8  0.5 9.0  0.1
Renal plasma flow, ml ·kg1 ·min1
(PAH) 30  4 30  1
Renal extraction, %
Inulin 29  2 25  2
CTGF 21  0.7 18  3
Tubular uptake of CTGF, % of
extracted amount 90.9  0.02 99.96  0.004
Fractional excretion of CTGF, % 0.10  0.02 0.025  0.006
Values are means  SE; n, no. of rats. CTGF, connective tissue growth
factor; GFR, glomerular filtration rate; PAH, para-aminohippuric acid.
Fig. 3. Effect of inhibition of proximal tubular reabsorption by Gelofusine in
mice. A: estimated renal levels of recombinant human N-CTGF 10–15 min
after iv N-CTGF administration in mice. Gelofusine administration before
N-CTGF injection (n  3) reduced renal N-CTGF accumulation compared
with saline pretreatment (n  3) (P  0.03, unpaired t-test). Gelofusine
administration did not affect plasma N-CTGF levels. B: urinary N-CTGF
levels during continuous infusion of recombinant human N-CTGF by ip
miniosmotic pump in 3 mice before (16 h urine collection) and within 1 h after
iv administration of Gelofusine bolus injection. Urinary N-CTGF increased
from 0.22  0.03 to 3.4  0.7 nmol/g creatinine (P  0.04; paired t-test).
Fig. 4. Effect of inhibition of proximal tubular reabsorption by Gelofusine in
humans. A: Gelofusine infusion for 60 min in 3 healthy volunteers (Œ,,)
induced a 23  1-fold increase in urinary CTGF (uCTGF) (P  0.004;
repeated-measures ANOVA) that was paralleled by an increase in urinary
2-microglobulin (u2M). B: uCTGF and u2M were tightly correlated before,
during, and after Gelofusine infusion.
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complete reabsorption in proximal tubular cells by megalin-
mediated endocytosis.
Our data show that both full-length and the NH2-CTGF
fragment are similarly handled by the kidney. For both CTGFs,
we observed extensive proximal tubular uptake in apical en-
docytic vesicles, very low FE (1%), and almost complete
tubular uptake of extracted CTGF (99%). We focused our
analyses on the NH2-terminal fragment of CTGF since this is
the predominant CTGF peptide in urine (6, 12, 19, 27) and
because the biomarker potential of CTGF has been studied
most extensively for this proteolytic fragment (1, 2, 6, 10, 12,
19, 24, 25, 27).
After intravenous administration in rats, renal extraction of
circulating NH2-CTGF was 74% of that of inulin. Because we
found no immunohistochemical evidence for basolateral up-
take in proximal tubular epithelial cells, we assume that most
of the extracted NH2-CTGF was filtered in the primary urine
by glomerular sieving, which would imply a sieving coefficient
of 	0.7. This is consistent with the observation that proteins
smaller than 20 kDa have sieving coefficients 0.5 (22). The
high degree of tubular reabsorption of filtered NH2-CTGF and
low FE are also in accordance with previously observed values
for other low molecular mass proteins, e.g., 2M (fractional
reabsorption 99.97%, FE 0.03%) and lysozyme (FE 0.4%) (3,
20, 33).
Impairment of proximal tubular reabsorption, either induced
by Gelofusine administration or in human renal disease, was
consistently associated with an increase in uCTGF excretion in
close correlation with that of 2M. Tubular dysfunction is an
important parameter in the assessment of renal damage. In
CKD, the degree of tubulointerstitial damage and the amount
of low molecular mass proteinuria are better predictors of
functional outcome than the severity of glomerular damage or
the total amount of proteinuria (8, 9). In DN, low molecular
mass proteinuria was found even before the occurrence of
microalbuminuria, probably representing a sign of incipient
DN (9, 15). Our results imply that uCTGF, reflecting proximal
tubular dysfunction, may be a valuable prognostic marker in
renal disease. Moreover, in contrast to known proximal tubular
dysfunction markers such as the biologically inert 2M and

1-microglobulin, luminal accumulation of CTGF and its frag-
ments might contribute actively to the pathogenic process (14,
23). Consistent with such a concept, uCTGF predicted progres-
sion of microalbuminuria in diabetic patients (29), and, in
another study, uCTGF independently predicted deterioration of
renal function in patients with iMN (1). However, the true
clinical value of uCTGF in renal disease still needs to be
established.
Although we show that uCTGF is highly dependent on
tubular function and tightly associated with u2M, the corre-
lation between the two proteins is not absolute (r2  0.72).
This might reflect disease-associated regulation of CTGF pro-
duction, either systemically or locally in different segments of
the nephron (16, 31). As expected for a filtered solute, plasma
CTGF was correlated with uCTGF in univariate analysis.
However, it did not emerge as an independent determinant in
multivariate analysis. The relative contribution of increased
local CTGF production could not be determined because the
Fig. 5. Correlation between log-transformed uCTGF and u2M in 108 chronic
kidney disease patients.
Fig. 6. Colocalization of N-CTGF and mega-
lin in the mouse kidney. Immunofluores-
cence of mouse kidney 10 min after iv ad-
ministration of recombinant human N-CTGF
and full-length CTGF by using human anti-
CTGF (green) and goat anti-megalin (red).
The N-terminal fragment and full-length
CTGF are located exclusively in megalin-
positive proximal tubules. Original magnifi-
cation 200.
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filtered load was unknown. Considering the virtually complete
proximal reabsorption from the primary urine in the healthy
kidney, CTGF produced in the glomeruli and released in the
luminal fluid will have limited impact on uCTGF as long as the
proximal endocytic apparatus is intact. On the other hand,
luminal secretion of CTGF expressed in distal tubules would
be expected to considerably affect uCTGF levels, but the
linearity of the relationship between u2M and uCTGF indi-
cates that tubular dysfunction is the major determinant of
uCTGF in the renal diseases included in our survey. However,
the relative contribution of increased local synthesis on uCTGF
in specific renal diseases remains to be elucidated in future
studies.
In conclusion, CTGF is reabsorbed almost completely from
the glomerular filtrate in proximal tubules via megalin-medi-
ated endocytosis in the healthy kidney, and elevated uCTGF
may largely reflect proximal tubular dysfunction. This should
be taken into account when using uCTGF as a biomarker and
in experimental work addressing its pathogenic involvement in
CKD.
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